TerraPower and Cardinal Health have formed an agreement that will help advance the next generation of cancer treatment. Under the agreement, the companies will work together to develop and produce Actinium-225 for use in drug development and commercial sales.   “Through TerraPower Isotopes, our team harnesses our focus on nuclear science and innovation and applies it to the health care sector to enable the development of targeted and potentially lifesaving cancer treatments,” said Scott Claunch,...